Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Core Viewpoint - Alkermes plc has initiated the phase II Vibrance-3 study for ALKS 2680, an oral orexin 2 receptor agonist, targeting idiopathic hypersomnia, a rare neurological sleep disorder [1][2]. Group 1: Study Details - The Vibrance-3 study is a double-blind, placebo-controlled trial assessing the safety and efficacy of ALKS 2680 in adults with idiopathic hypersomnia [2]. - The primary endpoint is to measure the reduction in sleepiness using the Epworth Sleepiness Scale score, comparing different dose levels of ALKS 2680 against placebo [2]. - Participants will receive one of three doses (10 mg, 14 mg, or 18 mg) or placebo daily for eight weeks, with secondary endpoints including changes in the Idiopathic Hypersomnia Severity Scale score and adverse event incidence [3]. Group 2: Market Performance - Year-to-date, Alkermes shares have increased by 13.1%, outperforming the industry average rise of 2.4% [4]. Group 3: Ongoing Research and Competition - ALKS 2680 is also being studied for narcolepsy type 1 and type 2 in the phase II Vibrance-1 and Vibrance-2 studies, respectively, with data expected in the second half of 2025 [5][6]. - Upon potential approval, ALKS 2680 may face competition from Axsome's Sunosi, which is already marketed for narcolepsy and has ongoing label expansion studies [7].